ACE inhibitors/ARBs have been shown to decrease the risk of progression of CKD in patients with proteinuria, although these agents have not been shown to reduce the progression to ESKD in nonproteinuric patients [4,5,6]. This evidence concerns the gene ACE and chronic kidney disease.